$ABEO

Abeona Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Generic
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$4.38 ▼-4.783%

Last Close

VOLUME

111,531

DAY RANGE

4.5 - 4.81

52 WEEK

0.1303 - 6.13

Join Discuss about ABEO with like-minded investors

profile
@CarlosH-carvan #ivtrades
recently

$ABEO mkt cap 26M.M.

136 Replies 7 👍 9 🔥

profile
@dros #droscrew
recently

Upgrades 11/30: $AYLA $BXMT $CAJ $ESMT $HHR $KRP $MAG $PTR $SQ $TTE $ZM . Downgrades 11/30: $ABEO $CENT $CGC $CQP $DLTR $FLMN $GDP $SEDG $SGTX $STNE $STXB $TROX $VG

107 Replies 14 👍 15 🔥

Key Metrics

Market Cap

28.38 M

Beta

2.13

Avg. Volume

273.45 K

Shares Outstanding

5.95 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-14

Next Dividend Date

Company Information

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.

CEO: Joao Siffert

Website:

HQ: 1330 Avenue of the Americas Fl 33 New York, 10019-5442 New York

Related News